## CDK8 Antibody


ebito / intibody					
Rabbit Polyclonal Antigen Affinity Purified		Protein ID	NP_001251.1		
Catalog No. A302-501A		GenelD	1024	DETUVI	
Lot No.	b. A302-501A-1			LABORATORIES, INC	
APPLICATIONS WB, IP, IHC		2			
SPECIES REACTIVI	TY Human	Human			
PRESUMED REACT	IVITY Based on	Based on 100% sequence identity, this antibody is predicted to react with Mouse			
AMOUNT	100 µl	100 µl			
CONCENTRATION	200 µg/m	200 µg/ml			
STORAGE/SHELF I	<b>LIFE</b> 2 – 8° C /	2 - 8° C / 1 year from date of receipt			
PHYSICAL STATE	Liquid	Liquid			
BUFFER	Tris-buffe	Tris-buffered Saline containing 0.1% BSA and 0.09% Sodium Azide			
ISOTYPE	lgG	lgG			
<b>ORIGIN</b> USA		SA			
PRODUCTION PROCEDURES	Antibody	Antibody was affinity purified using an epitope specific to CDK8 immobilized on solid support.			
	The epitope recognized by A302-501A maps to a region between residue 420 and 470 of H cyclin-dependent kinase 8 using the numbering given in entry NP_001251.1 (GeneID 1024				
		Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.			
APPLICATIONS		Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.			
	Western E	lot 1:2	2,000 - 1:10,000		
	Immunop	recipitation 2 -	- 5 µg/mg lysate		
	Immunoh		100 – 1:500. Epitope retriev commended for FFPE tissue	al with citrate buffer pH 6.0 is sections.	
APPLICATION NO	Goat anti-	Western blot of immunoprecipitates performed using Normal Pig Serum (Cat. No. S100–020), Goat anti–Rabbit Light Chain HRP Conjugate (Cat. No. A120–113P) and 4–20% SDS–PAGE (link to IP–western blot protocol in Additional Info section below).			
Western blot of lysates performed using standard western blot reagents and 4-20% SI IHC HUMAN CONTROLS Breast Carcinoma				n blot reagents and 4-20% SDS-PAGE.	
ADDITIONAL INFO	DDITIONAL INFOhttps://www.bethyl.com/product/A302-501AUse the link above to view SDS, a current list of citations, and other product specific informatiIP-western blot protocol: https://www.bethyl.com/content/protocol_IP_WB				

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc. Eric McIntush, PhD | Chief Scientific Officer Date: June 21, 2019


Bethyl Laboratories, Inc. • 25043 West FM 1097 • Montgomery, TX 77356 • 800.338.9579 • 936.597.6111 • 866.597.6105 (FAX) • www.bethyl.com • technical@bethyl.com

For in vitro laboratory use only. Not for any clinical, therapeutic or diagnostic use in humans or animals. Not for human or animal consumption. This product may not be resold or modified for resale without the prior written approval of Bethyl Laboratories, Inc. The information provided in this data sheet is believed to be correct but does not purport to be all-inclusive and is intended to be used as a guide. Bethyl Laboratories, Inc. shall not be liable or responsible in any way for use of either this information or the material supplied. Disposal of hazardous material may be subject to federal, state or local laws or regulations.

## **CDK8** Antibody



Detection of human CDK8 by western blot and immunoprecipitation. Samples: Whole cell lysate from HeLa (5, 15 and 50 µg for WB; 1 mg for IP, 20% of IP loaded) and HEK293T (T: 50 µg) cells. Antibodies: Affinity purified rabbit anti-CDK8 antibody A302-501A used for WB at 0.04 µg/ml (A) and 0.4 µg/ml (B) and used for IP at 3 µg/mg lysate. CDK8 was also immunoprecipitated by rabbit anti-CDK8 antibody A302-500A, which recognizes an upstream epitope. Detection: Chemiluminescence with exposure times of 3 minutes (A) and 30 seconds (B).



**Detection of human CDK8 by immunohistochemistry.** *Sample:* FFPE section of human breast carcinoma. *Antibody:* Affinity purified rabbit anti-CDK8 (Cat. No. A302-501A) used at a dilution of 1:200 (1µg/ml). *Detection:* DAB